Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

EMD Serono Receives Refuse to File Letter from FDA on Cladribine Tablets NewDrug Application

By Pharmaceutical Processing | November 30, 2009

EMD Serono, an affiliate of MerckKGaA, Darmstadt, Germany, announced today that it received a refuse to fileletter from the US Food and Drug Administration (FDA) on the New DrugApplication (NDA) for Cladribine Tablets, EMD Serono’s proprietaryinvestigational oral formulation of cladribine, as a therapy for relapsingforms of multiple sclerosis (MS). “The company will work closely with the FDA to fully understand FDA’sconcerns and define a path forward for a successful resubmission of thisapplication at the earliest point in time,” said Elmar Schnee, Member of theExecutive Board Merck KGaA and Head of Pharmaceuticals. “We remain focused ondelivering on our promise to transform the way people living with multiplesclerosis approach their therapy options.” Based on current regulations, once a NDA is submitted to the FDA, theAgency has 60 days to preliminarily review the NDA submission and assesswhether the NDA is sufficiently complete to permit a substantive review. If itdetermines that the NDA is not sufficiently complete, the FDA issues a refuseto file letter to the applicant. EMD Serono plans to request a meeting withthe FDA as soon as possible to discuss its comments on the NDA submission andto reach an understanding on what would be required for the Cladribine TabletsNDA to be accepted for review.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE